Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

OMCL exceeds Q1 2023 guidance, focuses on expansion and cost-saving

OMCL's Q1 2023 earnings call showcased strong financial performance, progress in integrating acquisitions, and a focus on cost-saving measures. The company also emphasized opportunities for expansion and addressed challenges related to operating expenses and inflation.

Omnicell exceeds Q2 revenue guidance, focuses on autonomous pharmacy

Omnicell's Q2 2023 earnings call highlighted strong performance, challenges in the healthcare industry, and the company's focus on accelerating the autonomous pharmacy. The company expressed confidence in its outlook for the second half of the year and emphasized the potential impact of a $9 billion payment to hospitals. Pricing actions have outweighed inflationary costs, and the XT upgrade process is progressing well.

OMCL reports Q3 2023 revenues of $299M, anticipates lower 2024 revenues

OMCL's Q3 2023 performance reflects a mix of solid financial results, market challenges, and strategic initiatives. The company is navigating lower revenue expectations and cost containment actions while focusing on driving outcomes through services and innovation. Despite the challenges, OMCL remains committed to returning to growth and seizing opportunities in the market.

OMCL reports Q4 2023 revenue decline but eyes 2024 stabilization

OMCL's Q4 2023 saw a decrease in total GAAP revenues, but they are optimistic about stabilization in 2024. The company is committed to transforming the pharmacy care delivery model and is focusing on enhancing services around their products. They are addressing challenges in advanced services and debt refinancing while aiming to drive growth and increased earnings.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Fort Worth, TX.

CECO Environmental Corp

Manulife Financial

Gibraltar Industries

SolarEdge Technologies

To safeguard one's portfolio from massive losses, the real challenge for an investor is to determine whether an organization's debt level is sustainable.

Buy These 5 Low Leverage Stocks to Keep Your Portfolio Safe

Syneos Health

SYNH vs. OMCL: Which Stock Is the Better Value Option?

SYNH vs. OMCL: Which Stock Should Value Investors Buy Now?

Omnicell (OMCL) continues to see solid segmental contributions in Q3. Expansion of gross and operating margins is a positive too.

Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View

Omnicell, Inc. (OMCL) CEO Randall Lipps on Q3 2019 Results - Earnings Call Transcript

Omnicell (OMCL) delivered earnings and revenue surprises of 5.56% and -1.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Q3 Earnings Surpass Estimates

Considering the weak penetration level in the international market, which is even less than 1%, Omnicell (OMCL) is rapidly exploring the uncharted overseas markets.

Omnicell Advances on Global Footing Despite Severe Rivalry

Omnicell (OMCL) aims to combine technology and innovation to enable pharmacists to expand their outreach to patients and improve services.

Omnicell's Autonomous Pharmacy to Boost Medication Management

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?

Omnicell (OMCL) Up 0.4% Since Last Earnings Report: Can It Continue?

Investor confidence continues to be high on Omnicell's (OMCL) prospects.

Here's Why You Should Hold Onto Omnicell (OMCL) Stock for Now

Omnicell (OMCL) aims at product innovation through R&D.

Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View

Omnicell, Inc. (OMCL) CEO Randall Lipps on Q2 2019 Results - Earnings Call Transcript

Omnicell (OMCL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Omnicell (OMCL) Catches Eye: Stock Jumps 8.2%

Shares of Omnicell rebounded Monday after the automated pharmacy company refuted claims from short-seller GlassHouse Research that it had prematurely recognized $38.3 million in revenue.
The post Medical Stock Refutes Damning Short-Seller Report — And Bounds Higher appeared first on Investor's Business Daily.

Medical Stock Refutes Damning Short-Seller Report — And Bounds Higher

Cadiz

GameStop

Despite the Dow hitting 27,000 for the first time, not every stock participated in the rally.

Why GameStop, Omnicell, and Cadiz Slumped Today

Omnicell tumbled Thursday after a short-seller accused the automated pharmacy company of "accounting gimmicks," including prematurely recording revenue and not writing off legacy inventory.

This Medical Stock Has Popped 78%; A Short-Seller Calls It A Scam

Omnicell (OMCL) is boosting investors' optimism, courtesy of consistent positive results.

Here's Why You Should Invest in Omnicell (OMCL) Stock Now

Why Is Omnicell (OMCL) Up 4.8% Since Last Earnings Report?

Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Will Omnicell (OMCL) Gain on Rising Earnings Estimates?

Omnicell (OMCL) gains from solid segmental contributions in Q1; margins expand.

Omnicell (OMCL) Earnings and Revenues Beat Estimates in Q1

Omnicell, Inc. (OMCL) CEO Randall Lipps on Q1 2019 Results - Earnings Call Transcript

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omnicell (OMCL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

News for Omnicell Stock (OMCL)